GT Biopharma Inc. (GTBP)
NASDAQ
Closed
Sep 18, 2026
Day's Range
7.1152 wk Range
0.2220Overview - GTBP - GT Biopharma Inc.
Key Statistics
Valuation
Enterprise Value
10.57M
P/E (Trailing)
‪0.06‬
P/E (Forward)
‪-0.79‬
PEG Ratio
‪-0.00066‬
Price / Book
‪4.31‬
EV / EBITDA
‪-14.48‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-158.15%‬
Return on Equity
‪-113.52%‬
Ownership
Shares Outstanding
1.80M
Float
1.70M
Short % of Shares Outstanding
‪8.52%‬
Price stats
Beta
‪0.90‬
50-Day Avg
‪8.14‬
200-Day Avg
‪11.78‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - GTBP - GT Biopharma Inc.
Peers - GTBP - GT Biopharma Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- GTBPNASDAQGT Biopharma Inc.20.98MMarket Cap+92.91%52-week change0.07P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - GTBP - GT Biopharma Inc.
About
GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
